Introduction
Walk into almost any clinical research site and you’ll find a binder, a shared drive folder, or an SOP titled something like “Ethics and Compliance.” It’s easy to file that material away mentally as background paperwork: necessary, but not where the real work happens.
That’s a mistake. According to the International Council for Harmonisation’s Good Clinical Practice guideline (ICH E6), ethical conduct is the first of thirteen core principles, and every other principle in the guideline rests on it. Trial design, data integrity, safety monitoring: none of it means much if the people who agreed to participate weren’t treated fairly, informed honestly, or protected when something went wrong.
For coordinators, investigators, and regulatory staff, ethics shows up less as a philosophical question and more as a series of everyday decisions: how a consent conversation goes, how quickly a safety signal gets escalated, how a translated form gets handled. The ten tips below focus on those decisions specifically, drawn from regulatory guidance, audit data, and research on how consent actually plays out at the bedside.
The chart below shows how often participants in one CenterWatch survey reported specific gaps in their understanding of the consent process, gaps that the tips below are designed to close.
Tips
1. Treat informed consent as a conversation, not a signature
A signed form is the record of a conversation, not a substitute for one. Participants need real time to ask questions, think things over, and talk to family before deciding, and a study from University Hospital Galway using the validated Quality of Informed Consent (QuIC) questionnaire found persistent gaps between what participants thought they’d agreed to and what the form actually said.
Walking through the key sections of the form together, rather than handing it over and waiting for a signature, closes most of that gap. Where the visit schedule allows it, let the participant take the document home before deciding.
2. Use only IRB-approved consent forms and translations
A non-English-speaking participant gets screened. There’s no approved translation for their language yet. The instinct is to have a bilingual staff member walk them through it verbally, and that instinct is the one to resist.
CenterWatch’s survey of clinical trial participants found that 41 percent had a study nurse review the consent form with them verbally, which helps, but it doesn’t substitute for an IRB-reviewed translated document when language is the actual barrier. An informal translation, however accurate, creates a mismatch between what the participant heard and what the approved paperwork says, and that mismatch is exactly the kind of inconsistency auditors are trained to spot. If the translation doesn’t exist yet, that’s a question for the IRB before enrollment, not a workaround for the visit.
3. Keep the consent document and protocol in sync
PMC’s review of cancer trial consent practices flags a recurring problem: the consent form says a procedure happens every visit, while the protocol specifies alternating visits. Nobody intended the discrepancy, but the participant was told something inaccurate regardless.
Cross-checking the consent form line by line against the schedule of events, every time a protocol amendment goes out, catches this before it becomes a finding.
4. Re-consent participants promptly when anything material changes
Consent isn’t a one-time event, and treating it that way is one of the most frequent and serious findings coordinators run into during site audits. If new safety information emerges, a protocol gets amended, or a procedure changes, the participant’s original signature no longer reflects the study they’re actually in.
A version tracker that flags every active participant affected by a consent form update turns this from a manual scramble into a routine check, even across a large enrolled population.
5. Build in time for participants under pressure
There’s a tension that shows up repeatedly in qualitative interviews with clinical research nurses: time constraints and information overload can quietly undermine whether consent is genuinely voluntary, particularly for patients facing serious or advanced illness. A participant who feels they have no real choice, or who’s overwhelmed during a single high-stakes visit, hasn’t given truly voluntary consent, even with a signature on file.
Offering a follow-up conversation rather than demanding an immediate decision, where the protocol allows it, addresses this directly.
6. Apply enhanced protections for vulnerable groups before enrollment starts
Children, people with limited literacy, economically disadvantaged participants, and other vulnerable groups need protections beyond what a standard adult consent process provides. PMC’s overview of IRB roles notes that ethics committees increasingly have to be proactive about how new consent methods and digital tools affect these populations, rather than assuming standard procedures are automatically adequate.
The safeguards that matter here, simplified language, independent advocates, extra decision-making time, belong in protocol design. Retrofitting them after enrollment has started is harder and less consistent.
7. Treat new safety information as a trigger to revisit consent
Say a safety signal turns up in another trial of the same product. The first question is whether it needs to be reported. The second, easy to skip, is whether it changes what your participants were told when they signed up.
If the answer to the second question is yes, updated consent language or direct communication with enrolled participants may be required, and that obligation doesn’t expire once enrollment closes.
8. Get the documentation right, completely and at the time
Missing signatures, missing dates, incomplete forms, incorrect consent versions. These show up constantly in audit data, and a descriptive analysis of FDA and EMA inspection findings grouped documentation and trial management as the two largest deficiency categories overall, with informed consent issues sitting inside both.
The fix is a one-minute habit: before a participant leaves a visit, confirm the consent version used and that every signature and date is complete.
9. Revisit the risk-benefit balance, not just at the start
ICH E6 is explicit that a trial should be initiated, and continued, only if the anticipated benefits justify the risks. What’s easy to forget is that this isn’t a calculation you make once during protocol design and file away.
As a trial progresses and new data accumulates, including data from entirely separate studies of the same product, the balance that justified the trial in the first place can shift. New efficacy or safety information mid-trial is worth treating as a prompt to actively revisit that justification, not just log and move on.
10. Make ethics training part of onboarding, and keep it current
Everyone on a trial, from data managers to investigators, needs both the qualifications and the trial-specific training their role demands under ICH E6, with retraining when protocols change or staff turn over.
Here’s why this lands on a list about consent specifically: training gaps tend to surface as consent-related findings first. The connection between “this person wasn’t retrained after the amendment” and “the wrong consent version is in this participant’s file” usually isn’t obvious until an auditor draws the line between them. A delegation log tying each team member’s responsibilities to current, documented training closes that gap before it becomes a finding.
Common Mistakes
The table below summarizes the gap between the mistake and the more durable practice.
| Common mistake | What to do instead |
|---|---|
| Treating consent as a one-time signed event | Build re-consent and ongoing communication into the study workflow from the start |
| Assuming “minimal risk” procedures don’t need careful consent | Apply the same standard of understanding regardless of how low-risk a procedure seems |
| Letting documentation lag behind practice | Check consent version, signatures, and dates before the participant leaves each visit |
| Improvising translations or verbal explanations | Flag missing translations to the IRB before enrollment rather than working around them |
| Treating ethics training as a one-time onboarding task | Tie training records to a delegation log and trigger retraining on protocol changes |
Additional Recommendations
Teams looking to go further should consider reviewing the full set of ICH E6(R2) principles directly rather than relying on summaries, since the guideline’s structure makes clear how interdependent these thirteen principles actually are. A consent version tracking system that automatically flags participants needing re-consent after a form update removes much of the manual burden described above.
For organizations updating their standard operating procedures around informed consent, particularly ahead of a sponsor audit or regulatory inspection, working with experienced regulatory and clinical research consulting partners can help ensure procedures reflect both current regulatory expectations and the practical realities of how consent actually happens at a busy site.
Sources
- Journal of Medical Internet Research, “Comparative Effectiveness of eConsent: Systematic Review” (2023)
- Egnyte, “Good Clinical Practice Standards for Ethical Clinical Trials”
- IntuitionLabs, “Good Clinical Practice (GCP): The 13 Principles Explained”
- PMC, “A New Look at Informed Consent for Cancer Clinical Trials”
- PMC, “Challenges regarding informed consent in recruitment to clinical research: a qualitative study of clinical research nurses’ experiences”
- CCRPS, “Understanding IRBs: Roles, Responsibilities and Ethics”
- PMC, “Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. FDA and European Medicines Agency”
- CenterWatch survey data, cited in USPTO patent application
- CCRPS, “Informed Consent for CRCs: Best Practices, Tools, and Compliance Tips”